< Back to latest news & events

Event

Salzburg Seminar: Patents, trademarks, intellectual property rights – how startups can act strategically

June 2025

Event date: 3rd June 2025

Young companies make many important decisions during the start-up phase. One of the most important questions is: How do I deal strategically with innovations, ideas, and brand development? Those who address intellectual property protection too late or make typical mistakes risk losing key corporate values.

In our specialist seminar “Patent and trademark strategy for start-ups – protecting innovation, building brands, securing growth,” we examine key aspects of intellectual property rights – from the initial idea to the growth phase. The seminar takes place at HGF in Salzburg and provides concrete recommendations for effectively developing an intellectual property rights strategy.

Seminar content

✔ When is a patent worthwhile – and when is it not?

✔ Protecting trademarks with limited resources

✔ Strategic use of intellectual property rights for investors and competition

✔ Avoiding common mistakes: What startups should know

Speaker: Bernhard Ganahl

The seminar will be led by Bernhard Ganahl, partner and patent attorney at HGF. With many years of experience in supporting technology-oriented startups, he provides practical insights into the development and implementation of effective patent and trademark strategies.

Who is the seminar suitable for?

The seminar is aimed at founders, startup managers, and anyone who wants to deal with intellectual property strategically—regardless of whether they already have prior knowledge or are just starting to ask questions.

📅 Date: June 3, 2025

🕔 Time: 5:30 p.m.

📍 Location: HGF, Rudolfskai 48, 5020 Salzburg, Austria

Secure your place now – participation is free of charge.

Latest updates

Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article